Value proposition

A nature-inspired solution to trap pathogens

@AIS Biotech (with AIS for Anti Infective Sugar) is a French Biotech company based in the @Région Auvergne-Rhône-Alpes, France, incorporated in March 2023 with the objective of developing a new class of sugar-based anti-infective biotherapeutics to fight (re)emerging infectious diseases.
Thanks to a Bioengineering plateform based on the expertise of the leading edge academic laboratory @CERMAV (@CNRS, @UGA, Grenoble, France), AIS Biotech aims to develop a pipeline of innovative sugar-based biopharmaceuticals which can prevent or treat infections by mimicking the natural host surface oligosaccharide binding-sites of pathogens.
GlycoFlu, our first drug-candidate validated at the preclinical stage by the #VirPath laboratory (@CIRI, @INSERM, @cnrs, @UCBL1, @ENS Lyon) and its Technology Research Platform @VirNext (@ucbl1), is developed to prevent or treat infections by human Influenza viruses, a global public health concern with a large socio-economic impact.